10 articles
Demis Hassabis confirmed that Isomorphic Labs' first AI-designed cancer drug will enter Phase 1 clinical trials in 2026, built on the AlphaFold-derived IsoDDE platform and backed by $3 billion in Lilly and Novartis partnerships.
Famous Labs launched Heisenberg, a quantum-informed AI platform that integrates electron-density molecular representations with ADMET and synthesis data to optimize molecule prioritization in drug discovery.
Isomorphic Labs unveiled IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy in protein-ligand prediction and identifies novel binding pockets from sequence alone, as the company prepares for its first clinical trials.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab in South San Francisco, combining Lilly's pharmaceutical expertise with NVIDIA's BioNeMo platform and Blackwell-powered supercomputing to reinvent drug discovery.
Insilico Medicine announced an $888M oncology partnership with Servier days after raising $292M in the largest Hong Kong biotech IPO of 2025, with shares surging 45% on debut.
David Baker's lab published RFdiffusion2 in Nature Methods, demonstrating an AI model that designs functional enzymes from scratch with catalytic activities approaching natural enzymes, alongside the open-source release of the faster RFdiffusion3.
Insilico Medicine and Hisun Pharma nominated a preclinical candidate in just 8 months using the Pharma.AI platform, dramatically compressing a process that typically takes 2.5 to 4 years in traditional drug discovery.
Chai Discovery raised $130M at a $1.3B valuation in December 2025, backed by OpenAI and others, after unveiling Chai-2 with a 100x improvement in zero-shot de novo antibody design and a 16% hit rate.
Intro AI has rapidly evolved from science fiction into a practical tool accelerating real scientific breakthroughs. In laboratories and research centers around the world, AI systems are crunching data, designing experiments, and even formulating...
Sprintome is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. From foundation models like Evo 2 and Alphafold 3 to synthetic data generation and agentic AI workflows — Next‑gen AI...